Comprehensive Pulmonary Safety Review of Inhaled Technosphere® Insulin in Patients with Diabetes Mellitus
نویسندگان
چکیده
منابع مشابه
Place of technosphere inhaled insulin in treatment of diabetes
Technosphere insulin (TI), Afrezza, is a powder form of short-acting regular insulin taken by oral inhalation with meals. Action of TI peaks after approximately 40-60 min and lasts for 2-3 h. TI is slightly less effective than subcutaneous insulin aspart, with mean hemoglobin A1c (HbA1c) reduction of 0.21% and 0.4%, respectively. When compared with technosphere inhaled placebo, the decrease in ...
متن کاملInhaled insulin in diabetes mellitus.
BACKGROUND Insulin therapy often relies on multiple daily injections of insulin. However this is a considerable burden to many people with diabetes and adherence to such an insulin regimen can be difficult to maintain, hence compromising optimal glycaemic control. Also, short acting injected insulin is absorbed more slowly than insulin released by the normal pancreas in response to a meal. Inha...
متن کاملEfficacy and Safety of Technosphere Inhaled Insulin Compared With Technosphere Powder Placebo in Insulin-Naive Type 2 Diabetes Suboptimally Controlled With Oral Agents
OBJECTIVE This double-blind, placebo-controlled, randomized, multicenter, parallel-group study compared the efficacy, safety, and tolerability of Technosphere insulin with Technosphere powder as placebo in insulin-naive type 2 diabetic patients whose diabetes was suboptimally controlled with oral antidiabetic agents. RESEARCH DESIGN AND METHODS Patients (n = 126) were randomly assigned to 12 ...
متن کاملEfficacy and Safety of Technosphere Inhaled Insulin Compared With Technosphere Powder Placebo in Insulin-Nave Type 2 Diabetes Inadequately Controlled with Oral Agents
From the Dallas Diabetes and Endocrine Center at Medical City, Dallas, Texas; the International Diabetes Center at Park Nicollet, Minneapolis, Minnesota; the University of Texas Health Science Center, San Antonio; the University of Washington Medical Center, Seattle; the Mills-Peninsula Health Services, San Mateo, California; MannKind Corporation, Paramus, New Jersey; and Johnson & Johnson Phar...
متن کاملTechnosphere insulin effectively controls postprandial glycemia in patients with type 2 diabetes mellitus.
BACKGROUND This pilot trial was designed to determine if an optimal dose of Technosphere(®) insulin (TI) inhalation powder (MannKind Corp., Valencia, CA) could be used regardless of variation in meal carbohydrate (CHO) content. SUBJECTS AND METHODS In total, eight subjects (seven men, one woman) with type 2 diabetes were enrolled. Subjects underwent dose optimization meal challenge (MC) visit...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Drug Investigation
سال: 2020
ISSN: 1173-2563,1179-1918
DOI: 10.1007/s40261-020-00958-8